Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


26.09.2022

2 Acta Neurol Scand
1 Brain
2 Diabetes
3 Intern Med
6 J Autoimmun
1 J Clin Endocrinol Metab
1 J Immunol
1 J Nephrol
3 J Neurol
3 J Rheumatol
1 Kidney Int
2 Lancet Neurol
6 Mult Scler
1 N Engl J Med
1 Nat Rev Neurol
2 Neurology
5 PLoS One
1 Thyroid


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neurol Scand

  1. MONTANES-MASIAS B, Bort-Roig J, Pascual JC, Soler J, et al
    Online psychological interventions to improve symptoms in multiple sclerosis: A systematic review: Online psychological interventions in Multiple Sclerosis.
    Acta Neurol Scand. 2022 Sep 19. doi: 10.1111/ane.13709.
    PubMed         Abstract available

  2. CUCE I, Altun Y
    Validity and reliability characteristics of the Silhouettes Fatigue Scale in measuring multiple sclerosis-related fatigue in Turkish-speaking adults.
    Acta Neurol Scand. 2022 Sep 19. doi: 10.1111/ane.13708.
    PubMed         Abstract available


    Brain

  3. VAN STEENHOVEN RW, Titulaer MJ
    Seronegative autoimmune encephalitis: exploring the unknown.
    Brain. 2022 Sep 16. pii: 6701799. doi: 10.1093.
    PubMed        


    Diabetes

  4. CORKEY BE, Kilpatrick LE, Evans-Molina C
    Hypothesis: Induction of Autoimmunity in Type 1 Diabetes-A Lipid Focus.
    Diabetes. 2022;71:2067-2074.
    PubMed         Abstract available

  5. KWON BC, Achenbach P, Anand V, Frohnert BI, et al
    Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals with Presymptomatic Type 1 Diabetes.
    Diabetes. 2022 Sep 16. pii: 147551. doi: 10.2337/db22-0360.
    PubMed         Abstract available


    Intern Med

  6. KANDA R, Nakano K, Nawata A, Iwata S, et al
    Remission of Granulomatosis with Polyangiitis Only After Resection of a Pulmonary Nodule.
    Intern Med. 2022;61:2803-2808.
    PubMed         Abstract available

  7. KODA N, Matsumoto K, Maruyama Y, Ishikawa N, et al
    A Case of a Pregnant Woman with IgA Nephropathy Showing Histological Preeclampsia Findings without Hypertension Treated with Steroids: A Case Report and Literature Review.
    Intern Med. 2022 Sep 21. doi: 10.2169/internalmedicine.9146.
    PubMed         Abstract available

  8. ZENIYA S, Sanjo N, Kuwahara H, Ishikawa K, et al
    Spinocerebellar Ataxia Type 31 Exacerbated by Anti-amino Terminal of Alpha-enolase Autoantibodies.
    Intern Med. 2022;61:2793-2796.
    PubMed         Abstract available


    J Autoimmun

  9. SAKURABA K, Krishnamurthy A, Sun J, Zheng X, et al
    Autoantibodies targeting malondialdehyde-modifications in rheumatoid arthritis regulate osteoclasts via inducing glycolysis and lipid biosynthesis.
    J Autoimmun. 2022;133:102903.
    PubMed         Abstract available

  10. LI X, Zhang Y, Wang J, Li Y, et al
    zVAD alleviates experimental autoimmune hepatitis in mice by increasing the sensitivity of macrophage to TNFR1-dependent necroptosis.
    J Autoimmun. 2022;133:102904.
    PubMed         Abstract available

  11. BAKER KF, Skelton AJ, Lendrem DW, Scadeng A, et al
    Erratum to "Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study" [J. Autoimmun. 105 (December 2019) 102298].
    J Autoimmun. 2022 Sep 19:102913. doi: 10.1016/j.jaut.2022.102913.
    PubMed        

  12. AZOULAY LD, Pineton de Chambrun M, Larcher R, Pene F, et al
    Prevalence, characteristics and outcome of cardiac manifestations in critically-ill antiphospholipid syndrome patients.
    J Autoimmun. 2022;133:102908.
    PubMed         Abstract available

  13. SCHOLZ GA, Fux M, Christ L, Iype J, et al
    Divergent regulatory T cell responses to high-dose methylprednisolone and tocilizumab in giant cell arteritis.
    J Autoimmun. 2022;133:102909.
    PubMed        

  14. ALVAREZ D, Rua C, Velasquez Berrio M, Catano JU, et al
    Extracellular vesicles released upon stimulation with antiphospholipid antibodies: An actual direct procoagulant mechanism or a new factor in the lupus anticoagulant paradox?
    J Autoimmun. 2022;133:102905.
    PubMed         Abstract available


    J Clin Endocrinol Metab

  15. DI FILIPPO L, Castellino L, Allora A, Frara S, et al
    Distinct clinical features of post COVID-19 vaccination early-onset Graves' disease (PoVEO GD).
    J Clin Endocrinol Metab. 2022 Sep 21. pii: 6708407. doi: 10.1210.
    PubMed         Abstract available


    J Immunol

  16. PARHAM KA, Tan XXS, Morelli DM, Chowdhury L, et al
    Pre-Germinal Center Interactions with T Cells Are Natural Checkpoints to Limit Autoimmune B Cell Responses.
    J Immunol. 2022 Sep 19. pii: jimmunol.2200534. doi: 10.4049/jimmunol.2200534.
    PubMed         Abstract available


    J Nephrol

  17. SEIKRIT C, Schimpf JI, Wied S, Stamellou E, et al
    Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study.
    J Nephrol. 2022 Sep 15. pii: 10.1007/s40620-022-01454.
    PubMed         Abstract available


    J Neurol

  18. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    PubMed        

  19. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    PubMed         Abstract available

  20. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    PubMed         Abstract available


    J Rheumatol

  21. DAVIS A, Faerber J, Ardalan K, Katcoff H, et al
    The Impact of Psychiatric Comorbidity on Health Care Utilization for Youth with Newly Diagnosed Systemic Lupus Erythematosus.
    J Rheumatol. 2022 Sep 15. pii: jrheum.220052. doi: 10.3899/jrheum.220052.
    PubMed         Abstract available

  22. STULL C, Sprow G, Werth VP
    Cutaneous Involvement in Systemic Lupus Erythematous: A Review for the Rheumatologist.
    J Rheumatol. 2022 Sep 15. pii: jrheum.220089. doi: 10.3899/jrheum.220089.
    PubMed         Abstract available

  23. XU A, Chen J, Wang X, Ye S, et al
    Pneumomediastinum and Subcutaneous Facial Emphysema in Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis.
    J Rheumatol. 2022 Sep 15. pii: jrheum.220521. doi: 10.3899/jrheum.220521.
    PubMed         Abstract available


    Kidney Int

  24. JACKSON SW, Alpers CE
    Lupus nephritis transcriptomics across space and time.
    Kidney Int. 2022;102:694-696.
    PubMed         Abstract available


    Lancet Neurol

  25. VILLEGA F, Pruss H, van Elst LT, Groc L, et al
    Cognitive and psychiatric features of anti-NMDA receptor encephalitis.
    Lancet Neurol. 2022;21:861-862.
    PubMed        

  26. GUASP M, Rosa-Justicia M, Munoz-Lopetegi A, Martinez-Hernandez E, et al
    Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders.
    Lancet Neurol. 2022;21:899-910.
    PubMed         Abstract available


    Mult Scler

  27. GAETANI L, Schoonheim MM
    Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Mult Scler. 2022;28:1831-1833.
    PubMed        

  28. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
    Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
    Mult Scler. 2022;28:1973-1982.
    PubMed         Abstract available

  29. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
    Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Mult Scler. 2022;28:1927-1936.
    PubMed         Abstract available

  30. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
    Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
    Mult Scler. 2022;28:1983-1996.
    PubMed         Abstract available

  31. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
    Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
    PubMed         Abstract available

  32. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
    Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
    Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
    PubMed         Abstract available


    N Engl J Med

  33. COLIZZO FP, Shroff SG, High FA, Chen YB, et al
    Case 29-2022: A 33-Year-Old Man with Chronic Diarrhea and Autoimmune Enteropathy.
    N Engl J Med. 2022;387:1124-1134.
    PubMed        


    Nat Rev Neurol

  34. WILLIAMS T, Chataway J
    Beyond ocrelizumab in primary progressive multiple sclerosis.
    Nat Rev Neurol. 2022 Sep 22. pii: 10.1038/s41582-022-00724.
    PubMed        


    Neurology

  35. BAARS AE, Kuitwaard K, de Koning LC, Luijten LWG, et al
    SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201376.
    PubMed         Abstract available

  36. ALLEN JA
    SARS-CoV-2 Vaccination and Autoimmune Neuropathies: Rebalancing the Risk.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201366.
    PubMed        


    PLoS One

  37. YOSHIKAWA H, Adachi Y, Nakamura Y, Kuriyama N, et al
    Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018.
    PLoS One. 2022;17:e0274161.
    PubMed         Abstract available

  38. CARREIRA M, Ruiz de Adana MS, Pinzon JL, Anarte-Ortiz MT, et al
    Internet-based Cognitive-behavioral therapy (CBT) for depressive symptomatology in individuals with type 1 diabetes (WEB_TDDI1 study): A randomized controlled trial protocol.
    PLoS One. 2022;17:e0274551.
    PubMed         Abstract available

  39. KUENDIG S, Kool J, Polhemus A, Schallert W, et al
    Three weeks of rehabilitation improves walking capacity but not daily physical activity in patients with multiple sclerosis with moderate to severe walking disability.
    PLoS One. 2022;17:e0274348.
    PubMed         Abstract available

  40. SMAOUI MR, Lafi A
    Leeno: Type 1 diabetes management training environment using smart algorithms.
    PLoS One. 2022;17:e0274534.
    PubMed         Abstract available

  41. NING L, Wang B
    Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0274565.
    PubMed         Abstract available


    Thyroid

  42. AHN HY, Lee J, Lee JK
    Predictive model for Graves' ophthalmopathy in patients with new-onset Graves' disease.
    Thyroid. 2022 Sep 21. doi: 10.1089/thy.2022.0280.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: